SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Izzy who wrote (5836)1/3/1999 11:49:00 PM
From: tommysdad  Read Replies (1) of 6136
 
Umm, Izzy, you're forgetting how many shares there are. DD is worth twenty times AGPH -- AGPH has a market cap of about $1.9 billion, DD about $58 billion. Yeah, DD could swallow AGPH whole, and probably pay cash for it. They got a bunch of cash from Merck when DuMPCo (DuPont-Merck Pharmaceutical Company) became part of DuPont again. They might want MTC too, mainly to get Celebrex -- the MTC/AHP fell through, so why not DD? DD has a big stake in Ag products and that is probably MTC's strength. Might get the "monopoly police" on their tail, though.

I still like DD buying AGPH -- but I'm not sure the research arm of DuPont Pharma would meld well with AGPH's research department. I know too many people at both places, and they just don't seem to have similar approaches to how they go about business. Could be ugly, from that perspective.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News